<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398420</url>
  </required_header>
  <id_info>
    <org_study_id>TVERP01</org_study_id>
    <nct_id>NCT04398420</nct_id>
  </id_info>
  <brief_title>Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP</brief_title>
  <official_title>Safety and Efficacy of TVERP in BPH Patients With Prostate Size ˃30 and ≤80 ml: a Comparison Study Between TVERP With the Plasma Vaporisation Button, Bipolar TURis and HoLEP Treatments.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympus Surgical Technologies Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olympus Surgical Technologies Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify the safety and efficacy of the use of the plasma vaporisation button in
      Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign
      prostatic hypertrophy (BPH) patients with prostate ˃30 and ≤80 ml compare to TURis or HoLEP
      surgery methods.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of blood level</measure>
    <time_frame>Measurement of pre-operative and immediate post-operative period (6 hours and 24 hours) hemoglobin and hematocrit levels will be performed.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Benign Prostatic Hypertrophy</condition>
  <arm_group>
    <arm_group_label>TVERP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TURis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HoLEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TVERP</intervention_name>
    <description>Transurethral Vapor Enucleation Resection of the prostate</description>
    <arm_group_label>TVERP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TURis</intervention_name>
    <description>Transurethral Vapor Enucleation Resection of the prostate</description>
    <arm_group_label>TURis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HoLEP</intervention_name>
    <description>Transurethral Vapor Enucleation Resection of the prostate</description>
    <arm_group_label>HoLEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, age older than 22 and younger than 75 years of age

          2. The patient should be a candidate for surgical treatment of bladder outlet
             obstruction.

          3. Patients with BPH and surgical indication (refractory to medical treatment, refractory
             or recurrent urinary retention, recurrent haematuria, bladder stones, recurrent
             infections, hydronephrosis)

          4. Prostate volume ˃30 and ≤80 ml

          5. PSA &lt;4 ng/ml in patients above 55 years old and a prostate cancer risk less than 35%.
             (Prostate cancer risk calculator).

          6. IPSS ≥8 (moderate to severe)

          7. Indications for TURIS

          8. maximum urinary flow (Qmax) &lt;10ml/second

          9. A written informed consent signed by the patient (including patient's agreement to
             randomization and treatment).

        Exclusion Criteria:

          1. Patients under anti-inflammatory or steroid therapy

          2. Patients under anti-coagulation at a level that could be exposed to a very high risk
             of complications based on a comprehensive pre-operatory evaluation.

          3. Renal insufficiency Serum creatinine (Scr) &gt;1.5 x upper limit of normal (ULN); AST and
             ALT&gt;2.5 x ULN;Total bilirubin &gt;1.5 x ULN

          4. Previous neurogenic lower urinary tract dysfunction.

          5. Patients with urethral strictures

          6. Severe pulmonary disease and cardio-vascular disorder 、Coagulopathy，and
             contraindications to anesthesia and surgery.

          7. Concurrent participation in any other clinical study

          8. Any of the following within the 12 months prior to study: myocardial infarction,
             uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
             heart failure, cerebrovascular accident or transient ischemic attack and 6 months for
             deep vein thrombosis or pulmonary embolism.

          9. Previous bladder outlet surgery.

         10. A clinically significant acute illness.

         11. Intake of medication in which the principle investigator considers to preclude
             enrollment into the trial.

         12. Known disease of the central or peripheral nervous system.

         13. Any clinical evidence of carcinoma of the prostate.

         14. HIV positive or any other immunosuppressive disorder.

         15. Psychological/psychiatric disease /Known cognitive disorder.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

